Stockreport

Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF Iclaprim met the primary endpointIclaprim was well tolerated in the study, with no nephrotoxicity observed Additional data from the previously announced results are incl [Read more]